Trial Watch-Immunostimulation with cytokines in cancer therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10323643" target="_blank" >RIV/00064203:_____/16:10323643 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/16:10323643
Result on the web
<a href="http://dx.doi.org/10.1080/2162402X.2015.1115942" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1115942</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2015.1115942" target="_blank" >10.1080/2162402X.2015.1115942</a>
Alternative languages
Result language
angličtina
Original language name
Trial Watch-Immunostimulation with cytokines in cancer therapy
Original language description
During the past decade, great efforts have been dedicated to the development of clinically relevant interventions that would trigger potent (and hence potentially curative) anticancer immune responses. Indeed, developing neoplasms normally establish local and systemic immunosuppressive networks that inhibit tumor-targeting immune effector cells, be them natural or elicited by (immuno) therapy. One possible approach to boost anticancer immunity consists in the (generally systemic) administration of recombinant immunostimulatory cytokines. In a limited number of oncological indications, immunostimulatory cytokines mediate clinical activity as standalone immunotherapeutic interventions. Most often, however, immunostimulatory cytokines are employed as immunological adjuvants, i.e., to unleash the immunogenic potential of other immunotherapeutic agents, like tumor-targeting vaccines and checkpoint blockers. Here, we discuss recent preclinical and clinical advances in the use of some cytokines as immunostimulatory agents in oncological indications.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
OncoImmunology [online]
ISSN
2162-402X
e-ISSN
—
Volume of the periodical
5
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
—
UT code for WoS article
000373385000045
EID of the result in the Scopus database
2-s2.0-84959386440